Battelino T, Bergenstal RM, Rodrguez A, Fernndez Land L, Bray R, Tong Z, et al
After adjustment of the model for weight loss, associations between the groups and headache outcomes did not remain statistically significant although a trend towards better headache outcomes in the GLP-1-RA group was noted
Drawing on academic and grey literature,6 as well as insights directly sourced from 38 subject experts (see Box 1), this report: Maps the medical innovation frontier
333-B1070, Nordic Biosite, Tby, Sweden) and the dipeptidyl peptidase (DPP)-4 inhibitor, sitagliptin (10 mg/kg, 5 uL/g, Xelevia
The best reps understand this: Access is earned before the conversation starts
for some [dulaglutide (Gerstein et al., 2019), liraglutide (Marso et al., 2016) and semaglutide (Marso et al., 2017)], the CVOTs also confirmed a cardiovascular benefit and eventually led to the approved use of these GLP-1 RAs to reduce cardiovascular risk in people with type 2 diabetes and established CVD or at high cardiovascular risk (Honigberg et al., 2020)